Phase 1 Study of EZN-2968 Weekly in Adult Patients With Advanced Solid Tumors or Lymphoma
Completed · Phase 1
Conditions studied: Carcinoma, Lymphoma
In brief
This is a Phase 1, open-label, non-randomized, dose-escalation study to determine the maximum tolerated dose (MTD), safety, tolerance, and pharmacologic profile of EZN-2968, a locked nucleic acid antisense oligonucleotide against hypoxia-inducible factor 1α administered as a 2-hour intravenous (i.v.) infusion weekly for 3 weeks per 6-week cycle. In patients treated at a recommended Phase 2 dose of EZN-2968, dose intensification will proceed by maintaining the dose, but gradually increasing the number of doses per 6-week cycle. Up to 3 intensification cohorts will receive the recommended Phase 2 dose of EZN-2968.
Key facts
- Study ID
- NCT00466583
- Run by
- Enzon Pharmaceuticals, Inc.
- People needed
- 52
- Starts
- 2007-03-01
- Expected to finish
- 2011-06-01
- Last updated by the study team
- 2011-07-07
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Duke University Medical Center — Durham, North Carolina, United States
- Fox Chase Cancer Center — Philadelphia, Pennsylvania, United States
- Joe Arrington Cancer Research and Treatment Center — Lubbock, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.